Day after ICMR's clarification on coronavirus vaccine, IASc calls timeline 'unprecedented and unfeasible'
A day after the ICMR announced that it aims to launch a COVID-19 vaccine by 15 August, it issued a clarification saying the process to expedite trials was in accordance with norms
The 15 August deadline set by the Indian Council of Medical Research for Bharat Biotech India Limited to launch a coronavirus vaccine is “unfeasible and has raised unrealistic hopes” in the minds of the people, the Indian Academy of Sciences (IASc) said in a statement.
“The Academy strongly believes that any hasty solution that may compromise rigorous scientific processes and standards will likely have long-term adverse impacts of unforeseen magnitude on citizens of India,” the statement said.
The statement referred to a letter by ICMR director-general Balram Bhargava which stated the hospitals selected for phase 1 and phase 2 trials, and said that “it is envisaged to launch the vaccine for public health use latest by 15 August, 2020 after completion of all clinical trials”.
The IASc said that the timeline is “unreasonable and without precedent”, the statement said adding that vaccine development requires scientifically executed trials in a phased manner. Despite the “unquestioned urgent need”, the vaccine has to go through the three phases to evaluate safety, efficacy and side effects, and confirmation of safety before release for public use.
“Clinical trials for a candidate vaccine require the participation of healthy human volunteers. Therefore, many ethical and regulatory approvals need to be obtained prior to the initiation of the trials. While administrative approvals can be expedited, the scientific processes of experimentation and data collection have a natural time span that cannot be hastened without compromising standards of scientific rigour. Data collected in one phase must be adequately analysed before next phase can be initiated. If the data of any phases are unacceptable, then the clinical trial is required to be immediately aborted,” the statement read.
— Anant Bhan (@AnantBhan) July 5, 2020
The candidate vaccine in question was developed by BBIL in collaboration with ICMR’s National Institute of Virology and was granted approval for phase 1 and 2 trials a week ago. After criticism of the ICMR’s announcement of a 15 August deadline to release the vaccine for public use, the body said in a statement that the 2 July letter designating hospitals for trials and seeking the expedition of the process was meant to “cut unnecessary red tape”.
“Just as red tape was not allowed to become a hindrance in the fast-track approval of the new indigenous testing kits for introducing in the Indian market, the indigenous vaccine development process has also been sought to be insulated from slow file movement,” ICMR said in a statement on Saturday.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
Hard to predict likelihood of second wave of COVID-19 infections in India, ICMR DG says as case tally crosses 18 lakh
ICMR reportedly co-developed a platform with other 10 Southeast Asian countries to conduct collaborative research on emerging diseases.
US officials say COVID-19 vaccine will be distributed for free to all Americans, vow 'no shortcuts' on safety
The president's critics have expressed worry that the administration may bypass safety precautions to announce a vaccine before the election
Coronavirus Updates: Bihar aims to conduct over 1 lakh COVID-19 tests daily after PM says state lags behind in testing
Coronavirus LIVE Updates: Bihar chief minister Nitish Kumar Tuesday told Prime Minister Narendra Modi that the state plans to raise testing rate for COVID-19 to over one lakh per day.